JDRF’s Relationship with Genentech Helps Support Eyesight-Saving Drug

The collaborative relationship between JDRF and Genentech contributed vital information about the performance of this drug, which can provide an immediate treatment for a serious diabetes-related complication that affects adults living with type 1 diabetes. We are pleased to see the European approval of Lucentis, a first-time treatment for diabetes-related eye disease, and JDRF continues to advocate for the approval of Lucentis in the United States.